Goldstone Anthony H
Department of Haematology, University College London Hospitals, London NW1 2BU, United Kingdom.
Clin Lymphoma Myeloma. 2009;9 Suppl 3:S211-3. doi: 10.3816/CLM.2009.s.014.
The large MRC/ECOG Adult Acute Lymphoblastic Leukemia Study establishes the value of sibling donor allogeneic transplantation in patients with standard risk, demonstrating superior outcome to conventional chemotherapy. The small but significant number of patients having matched unrelated donor transplantations on this study protocol appear to do well and might establish the value of such an approach for those without a sibling. Reduced-intensity conditioning might begin to address the transplantation-related mortality problems of the older patients. The youngest adults might not need to undergo transplantation at all. If they are now treated on pediatric chemotherapy protocols, their outcome appears to improve significantly.
大型医学研究委员会/东部肿瘤协作组成人急性淋巴细胞白血病研究确定了同胞供体异基因移植在标准风险患者中的价值,表明其疗效优于传统化疗。在本研究方案中接受匹配无关供体移植的患者数量虽少但具有显著意义,他们似乎预后良好,这可能为那些没有同胞供体的患者确立了这种方法的价值。降低强度预处理可能开始解决老年患者与移植相关的死亡问题。最年轻的成年人可能根本不需要进行移植。如果他们现在按照儿童化疗方案进行治疗,其预后似乎会显著改善。